Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Wednesday Apr 20, 2022
Wednesday Apr 20, 2022
touchCONGRESS for touchONCOLOGY
Listen to Prof. Isabelle Ray-Coquard (France) cover key data presented at SGO 2022 on PARP inhibitors as first-line maintenance therapy in ovarian cancer, and their implications for clinical practice, including expert insights and interpretation from Dr Antonio González-Martín (Spain) and Dr Sandro Pignata (Italy).
OVERVIEW
- Data review with Prof. Ray-Coquard (0:32)
- Expert interviews with Dr González-Martín, Dr Pignata and
Prof. Ray-Coquard, answering the questions below
INTERVIEW QUESTIONS
-
- How have the clinical trial data regarding first-line maintenance with PARP inhibitors in patients with ovarian cancer changed our understanding of the efficacy of these treatments? (22:56)
- What have we learned about managing adverse events in patients with ovarian cancer receiving first-line maintenance with PARP inhibitors? (29:21)
- Based on the presentations at SGO 2022, are you likely to change how you personalize treatment by considering the patient’s molecular characteristics? (36:32)
- What can we learn from the real-world evidence for first-line maintenance with PARP inhibitors presented at SGO 2022? (43:15)
- How do you see the role and optimization of PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer evolving in the next 5 years? (49:39)
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/parp-inhibitors-maintenance-sgo2022/
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.